

LIST OF FIGURES

Figure No.	Title	Page No.
Figure: 2.1	WHO pain Ladder (from WHO Guidelines)	14
Figure: 2.2	Pain pathway	15
Figure: 2.3	Schematic representation of BBB	22
Figure: 2.4	Schematic comparison between brain (left) and general (right) capillaries	22
Figure: 2.5	(A) Blood Brain Barrier (B) Blood cerebrospinal fluid Barrier	25
Figure: 2.6	Nasal vascular supply	33
Figure: 2.7	Location of the olfactory bulb, the olfactory mucosa and the olfactory nerve cells in humans Modified picture from the Nobel Prize official homepage	34
Figure: 2.8	Nose to brain transport routes	35
Figure: 2.9	Structure of chitin and chitosan	47
Figure: 2.10	Schematic overview of the mechanism of chitosan as a permeation enhancer	49
Figure: 2.11	Various type of drug loaded nanoparticles	53
Figure: 2.12	Preparation method of chitosan nanoparticles using Ionotropic gelation method	54
Figure: 2.13	Simple diagrammatic representation of preparing thiolated polymer	57
Figure: 2.14	Mechanism of disulphide bond formation between thiomers and mucus glycoproteins (Mucins) (Sreenivas et al.,2008)	57
Figure: 2.15	Structure of chitosan and thiolated chitosan	59
Figure: 2.16	Schematic presentation of improved mucoadhesion by an insitu cross-linking in comparison to chain links	63
Figure: 2.17	Synthesis of trimethyl chitosan	66
Figure: 2.18	Alkylation of chitosan followed by quarternisation	69
Figure: 2.19	FTIR spectra of the chitosan DD 96% (____), TMC DQ 52.5% (- - -) and TMC DQ 27% (.....)	71
Figure: 3.1	Regressed calibration curve for estimation of Tizanidine HCl in distilled water	98

Figure: 3.2	Regressed calibration curve for estimation of Tizanidine HCl in phosphate buffer (pH 5)	100
Figure: 3.3	Regressed calibration curve for estimation of Cyclobenzaprine HCl in distilled water	101
Figure: 3.4	Regressed calibration curve for estimation of Cyclobenzaprine HCl in phosphate buffer (pH 5)	103
Figure: 3.5	HPLC Chromatogram for Tizanidine HCl	105
Figure: 3.6	Regressed calibration curve for estimation of Tizanidine HCl	105
Figure: 3.7	HPLC Chromatogram for Cyclobenzaprine HCl	107
Figure: 3.8	Regressed calibration curve for estimation of Cyclobenzaprine HCl	108
Figure: 3.9	Regressed calibration curve for estimation of Rhodamine B in distilled water	109
Figure:4.1	a) Structure of Ellman's Reagent (b) Reduction of Ellman's Reagent	116
Figure:4.2	Infrared spectra: (a) Low molecular weight chitosan (b) Medium Molecular weight chitosan (c) Low molecular weight thiolated chitosan (d) Medium Molecular weight thiolated chitosan	120
Figure:4.3	Change in observed particle size and zeta potential of ss-mucin particles when mixed with the various volumes of 1 mg/ml polymer solution (a) LMC (b)MMC(c)LMTC (d) MMTC	123
Figure:4.4	Synthesis of trimethyl chitosan	125
Figure:4.5	Infrared spectrum: (a) Low molecular weight chitosan (b) Medium molecular weight chitosan (c) Low molecular weight trimethyl chitosan (d) Medium molecular weight trimethyl chitosan	127
Figure:4.6	¹ H MNR spectra of: (a) Low molecular weight trimethyl chitosan (b) Medium molecular weight trimethyl chitosan	129
Figure:4.7	Change in observed particle size and zeta potential of ss-mucin particles when mixed with the various volumes of 1 mg/ml polymer solution (a) LMC (b)MMC((c)LMTMC (d) MMTMC	131
Figure:5.1	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the particle size of the LMC-TZ NPs	143
Figure:5.2	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the entrapment efficiency of the LMC-TZ NPs	144

Figure:5.3	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the particle size of the LMC-CBZ NPs	145
Figure:5.4	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the entrapment efficiency of the LMC-CBZ NPs	146
Figure:5.5	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the particle size of the MMC-TZ NPs	147
Figure:5.6	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the entrapment efficiency of the MMC-TZ NPs	148
Figure:5.7	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the particle size of the MMC-CBZ NPs	149
Figure:5.8	Response surface and contour plots of a) the effects of Concentration of chitosan (A) and Concentration of sodium alginate (B), b) effects of Concentration of chitosan (A) and Concentration of drug (C) and c) Concentration of sodium alginate (B) and Concentration of Drug (C) on the entrapment efficiency of the MMC-CBZ NPs	150
Figure:5.9	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the LMTC-TZ NPs	163

Figure:5.10	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the LMTC-TZ NPs	165
Figure:5.11	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the LMTC-CBZ NPs	167
Figure:5.12	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the LMTC-CBZ NPs	169
Figure:5.13	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the MMTC-TZ NPs	171

Figure:5.14	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the MMTC-TZ NPs	173
Figure:5.15	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the MMTC-CBZ NPs	175
Figure:5.16	Response surface and contour plots of a) the effects of Concentration of thiolated chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of thiolated chitosan (A) and Concentration of drug (C) c) Concentration of thiolated chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the MMTC-CBZ NPs	177
Figure:5.17	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the LMTMC-TZ NPs	189

Figure:5.18	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the LMTMC-TZ NPs	191
Figure:5.19	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the LMTMC-CBZ NPs	193
Figure:5.20	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the LMTMC-CBZ NPs	195
Figure:5.21	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the MMTMC-TZ NPs	197

Figure:5.22	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment efficiency of the MMTMC-TZ NPs	199
Figure:5.23	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the particle size of the MMTMC-CBZ NPs	201
Figure:5.24	Response surface and contour plots of a) the effects of Concentration of trimethyl chitosan (A) and Concentration of sodium alginate (B) b) effects of Concentration of trimethyl (A) and Concentration of drug (C) c) Concentration of trimethyl chitosan (A) and concentration of sodium deoxycholate (D) d) Concentration of sodium alginate (B) and Concentration of Drug (C) e) Concentration of sodium alginate (B) and concentration of sodium deoxycholate (D) f) Concentration of drug (C) and concentration of sodium deoxycholate (D) on the entrapment of the MMTMC-CBZ NPs	203
Figure:6.1	Particle size distribution plots of : (a) LMC-TZ NPs (b) LMC-CBZ NPs(c) MMC-TZ NPs (d) MMC-CBZ NPs (e) LMTC-TZ NPs (f) LMTC-CBZ NPs (g) MMTC-TZ NPs (h) MMTC-CBZ NPs (i) LMTMC-TZ NPs (j) LMTMC-CBZ NPs (k) MMTMC-TZ NPs (l) MMTMC-CBZ NPs	253
Figure:6.2	Zeta potential plots of : (a) LMC-TZ NPs (b) LMC-CBZ NPs(c) MMCTZ NPs (d) MMC-CBZ NPs (e) LMTC-TZ NPs (f) LMTC-CBZ NPs (g) MMTC-TZ NPs (h) MMTC-CBZ NPs (i) LMTMC-TZ NPs (j) LMTMC-CBZ NPs (k) MMTMC-TZ NPs (l) MMTMC-CBZ NPs	257
Figure:6.3	(a) <i>In -vitro</i> release of tizanidine HCl from chitosan, thiolated chitosan and trimethyl chitosan NPs using dialysis bag (b) <i>In -vitro</i> release of cyclobenzaprine HCl from chitosan, thiolated chitosan and trimethyl chitosan NPs using dialysis bag	259

Figure:6.4	(a) <i>In -vitro</i> release of tizanidine HCl from chitosan, thiolated chitosan and trimethyl chitosan NPs using nasal mucosa (b) <i>In -vitro</i> release of cyclobenzaprine HCl from chitosan, thiolated chitosan and trimethyl chitosan NPs using nasal mucosa	260
Figure:6.5	TEM image of : (a) LMC-TZ NPs (b) LMC-CBZ NPs(c) MMC-TZ NPs (d) MMC-CBZ NPs (e) LMTC-TZ NPs (f) LMTC-CBZ NPs (g) MMTC-TZ NPs (h) MMTC-CBZ NPs (i) LMTMC-TZ NPs (j) LMTMC-CBZ NPs (k) MMTMC-TZ NPs (l) MMTMC-CBZ NPs	262
Figure:6.6	Histopathological evaluations of sections of sheep nasal mucosal membrane: a) LMC-TZ NPs (b) LMC-CBZ NPs(c) MMC-TZ NPs (d) MMCCBZ NPs (e) LMTC-TZ NPs (f) LMTC-CBZ NPs (g) MMTC-TZ NPs (h) MMTC-CBZ NPs (i) LMTMC-TZ NPs (j) LMTMC-CBZ NPs (k) MMTMC-TZ NPs (l) MMTMC-CBZ NPs (m) Phosphate buffer (pH 6.4) (n) IPA	265
Figure:6.7	Confocal images of Mucosal surface: (a) LMC-RB NPs (b) MMC-RB NPs(c) LMTC-RB NPs (d) MMTC-RB NPs (e) LMTMC-RB NPs (f) MMTMCRB NPs (g)RB solution	266
Figure:6.8	Confocal images after Z sectioning of nasal mucosa: (a) LMC-RB NPs (b) MMC-RB NPs(c) LMTC-RB NPs (d) MMTC-RB NPs (e) LMTMC-RB NPs (f) MMTMC-RB NPs (g) RB solution	267
Figure:7.1	Stability profiles of tizanidine HCl loaded chitosan, thiolated chitosan and trimethyl chitosan NPs on particle size	280
Figure:7.2	Stability profiles of cyclobenzaprine HCl loaded chitosan, thiolated chitosan and trimethyl chitosan NPs on particle size	280
Figure:7.3	Stability profiles of tizanidine HCl loaded chitosan, thiolated chitosan and trimethyl chitosan NPs on Zeta potential	281
Figure:7.4	Stability profiles of cyclobenzaprine HCl loaded chitosan, thiolated chitosan and trimethyl chitosan NPs on Zeta potential	281
Figure:7.5	Stability profiles of tizanidine HCl loaded chitosan, thiolated chitosan and trimethyl chitosan NPs on Drug content	282
Figure:7.6	Stability profiles of cyclobenzaprine HCl loaded chitosan, thiolated chitosan and trimethyl chitosan NPs on Drug content	282
Figure:8.1	Reduction of MTT using mitochondrial reductase	288
Figure:8.2	Cell viability study of chitosan, thiolated chitosan trimethyl chitosan and its tizanidine HCl loaded NPs formulations	296
Figure:8.3	Cell viability study of chitosan, thiolated chitosan trimethyl chitosan and its cyclobenzaprine HCl loaded NPs formulations	297
Figure:9.1	Blood, brain concentration versus time plot following administration of ^{99m} Tc-Tizanidine HCl formulations	320
Figure:9.2	Blood, brain concentration versus time plot following administration of ^{99m} Tc-Cyclobenzaprine HCl formulations	321

Figure:9.3	Gamma scintigraphy images of (a) ^{99m}Tc -TZ solution (i.v.) (b) ^{99m}Tc -TZ solution (oral) (c) ^{99m}Tc -TZ solution (i.n.) (d) ^{99m}Tc -LMC-TZ NPs (e) ^{99m}Tc -MMC-TZ NPs (f) ^{99m}Tc -LMTC-TZ NPs (g) ^{99m}Tc -MMTC-TZ NPs (h) ^{99m}Tc -LMTMC-TZ NPs (i) ^{99m}Tc -MMTMC-TZ NPs in swiss albino mice	324
Figure:9.4	Gamma scintigraphy images of (a) ^{99m}Tc -CBZ solution (i.v.) (b) ^{99m}Tc - CBZ solution (oral) (c) ^{99m}Tc - CBZ solution (i.n.) (d) ^{99m}Tc -LMC- CBZ NPs (e) ^{99m}Tc -MMC- CBZ NPs (f) ^{99m}Tc -LMTC- CBZ NPs (g) ^{99m}Tc -MMTC- CBZ NPs (h) ^{99m}Tc -LMTMC- CBZ NPs (i) ^{99m}Tc -MMTMC- CBZ NPs in swiss albino mice	324
Figure:10.1	Effect of CBZ formulations on hyperalgesia induced by intrathecal administration of NMDA in mice hot plate test	335
Figure 10.2	Antinociceptive Effect of TZ formulations on mice hot plate test	336